Vision
To advance the development and utilization of safe and efficacious medicines through the application of Quantitative Systems Pharmacology (QSP)
- Advance the science of QSP by fostering a community for the exchange of ideas and knowledge
- Promote the application of QSP in drug development and regulatory decision-making
- Develop and maintain information resources for its members, including establishment of “best practices” for QSP approaches
- Facilitate communication and advance knowledge through sponsored sessions at professional meetings, white papers, discussion groups, and publications
QSP SIG Leadership Team
|
Dr. Brian J. Schmidt is a senior principal scientist in quantitative systems pharmacology within clinical pharmacology & pharmacometrics at Bristol-Myers Squibb. Brian earned his PhD in Biomedical Engineering at the University of Virginia. He received postdoctoral training in systems biology and computational biology at the University of Virginia; University of California, San Diego; and Sanford-Burnham Medical Research Institute. He also previously performed research as a dynamics engineer in QSP at Entelos, where he developed and applied mechanistic models in multiple therapeutic areas, including autoimmune, cardiovascular disease, and type 2 diabetes. He is currently leading a group responsible for the development and application of QSP platforms to support clinical development in oncology and immuno-oncology. His contributions cover multiple facets QSP, including model development, the development of new algorithms for calibrating mechanistic models to data, the development of software tools to support QSP, application of QSP to improve decision making throughout clinical development, and the application of QSP models in regulatory interactions. |
|
Dr. Friedrich is the Chief Engineer at Rosa & Co, a drug development advisory firm that specializes in mechanistic QSP modeling. She holds BS degrees in Mathematics and Engineering Systems and Computation from MIT and a PhD in Management Science and Engineering from Stanford University. Dr. Friedrich has over 18 years of experience in developing and applying mathematical models of biological systems to support development of pharmaceuticals and consumer products. Her therapeutic area experience includes diabetes, blood disorders, CNS disorders, oncology/immuno-oncology, respiratory diseases, skin diseases, auto-immune diseases, and other immune system dysfunctions and inflammatory processes. Dr. Friedrich has a long-standing interest in advancing methodologies and applications for the effective use of mechanistic QSP models. While at Rosa, Dr. Friedrich developed and published the Model Qualification Method, a systematic qualification framework for mechanistic mathematical QSP models. In her previous role at Entelos, Dr. Friedrich spearheaded development of modeling methodologies and contributed to foundational mechanistic modeling patents, including on the use of virtual patients and virtual populations to explore biological variability and uncertainty, and on the use of mechanistic models in the identification of biomarkers. |
|
Dr. Benjamin Ribba holds a Master degree and PhD in applied mathematics. He started his career in 2001 as a fellow of a European Research Grant dedicated to application of mathematics to biology and medicine. He was successively researcher in computer science at Inria from 2008 to 2015 in France where he focused his research on the development and application of mathematical models to address questions around optimization of the efficacy and delivery of anti-cancer drugs in patients. In 2015, he joined Roche Pharma Research and Early Development. He is the author of ca. 50 publications in peer-reviewed scientific journals. |
|
Dr. Abhishek Gulati is an Associate Director in the New Technologies Group within the Clinical Pharmacology and Exploratory Development at Astellas Pharma. Dr. Gulati received his Ph.D. in Pharmacometrics and Systems Pharmacology from University of Otago, New Zealand, and obtained Postdoctoral training at Indiana University, focusing on several modeling aspects in the cardiovascular, pulmonary and neuroscience therapeutic areas. At Astellas, he is leading the Quantitative Systems Pharmacology efforts in the Immunology and Immuno-oncology therapeutic areas, including vaccines and cell therapies. He is also actively working on developing novel visualization tools for reporting multi-scale mechanistic models. Prior to joining the Leadership Team, he has been deeply involved with the QSP SIG’s initiatives, serving as a co-chair of the iPSP Working Group. |
|
Eric Sobie is a biomedical engineer by training and a systems pharmacologist by choice. He received his B.S. degree from Duke University, and his Ph.D. from Johns Hopkins, both in Biomedical Engineering. After postdoctoral training at the University of Maryland, he established an independent laboratory in the Department of Pharmacology at Icahn School of Medicine at Mount Sinai. At Mount Sinai, his NIH-funded laboratory aims to uncover fundamental mechanisms and improve drug development by combining physiological experiments with mathematical modeling. Specifically, his group has made important advances in understanding differences between individuals in response to pro-arrhythmic drugs, in using modeling to identify targets with improved anti-arrhythmic properties, and in developing algorithms to distinguish between dangerous and safe cardiac drugs. In addition to running a research laboratory, Eric also serves as Associate Dean for Programmatic Development in Mount Sinai’s graduate school. |
|
Dr. Peter Bloomingdale is a Senior Scientist in the Quantitative Pharmacology & Pharmacometrics (QP2) group at Merck. Peter obtained his PhD in Pharmaceutical Sciences from the University at Buffalo. Peter’s interests lie in leveraging a combination of quantitative systems pharmacology and machine learning approaches to augment the drug discovery and development process. At Merck, Peter provides modeling and simulation support to programs in the neuroscience therapeutic area and is responsible for developing PK/PD/systems models for applications ranging from target identification/validation to clinical dose selection. |
Brian Schmidt (Chair)
Christina Friedrich (Chair-Elect )
Benjamin Ribba (Vice-Chair)
Abhishek Gulati (Communications Director)
Eric Sobie (Past Chair)
Peter Bloomingdale (Secretary)2020 Steering Committee Members
- Jane Bai, PhD, Office of Clinical Pharmacology, Division of Applied Regulatory Science, United States Food and Drug Administration
- John Burke, PhD, President, CEO, and Co-founder at Applied BioMath, Adjunct Faculty, Harvard Medical School
- James Gallo, PharmD, PhD, Empire State Innovation Professor, SUNY Buffalo Department of Pharmaceutical Sciences
- Rukmini Kumar, PhD, Chief Scientist and Co-founder, Vantage Research
- Tarek Leil, PhD, Group Director, Quantitative Clinical Pharmacology, BMS, Adjunct Faculty, University of Pittsburgh School of Pharmacy
- CJ Musante, PhD, Senior Scientific Director, Head of Quantitative Systems Pharmacology, Pfizer
- Mark Peterson, PhD, Senior Director, Modeling & Simulation, Vertex
- Aleksander S. Popel, Professor, Department of Biomedical Engineering, School of Medicine, Johns Hopkins University
- Saroja Ramanujan, PhD, Principal Scientist & Associate Director, Translational & Systems Pharmacology, Head of QSP, Genentech Inc.
- Matthew Riggs, PhD, Chief Science Officer, Metrum Research Group
- Julio Saez-Rodriguez, PhD, Professor of Medical Bioinformatics and Data Analysis, Heidelberg University Hospital, Group Leader, EMBL
- Stephan Schmidt, PhD, FCP, Endowed Certara Professor, University of Florida College of Pharmacy
- Birgit Schoeberl, PhD, Global Head Modeling and Simulation, PK Sciences at Novartis Institutes for BioMedical Research
- Iñaki F. Trocóniz, PhD, Professor, Universidad de Navarra, Pharmacometrics & Systems Pharmacology
- Piet van der Graaf, PhD, Senior Vice President QSP, Certara, Professor of Systems Pharmacology, Leiden University
- Paolo Vicini, PhD, Vice President, Development Sciences, Kymab Ltd
What is Quantitative Systems Pharmacology?
The white paper below represents the NIH’s attempt to define the
opportunities and challenges facing the field of quantitative systems
pharmacology (QSP). The paper recommends the adoption of a holistic
approach to understanding the interaction of drugs with human biology.
The paper further notes that this will require the collaboration and
training of scientists from multiple disciplines, from pharmacology to
chemistry to computer science. We look forward to hearing from ideas
from our SIG members about how these disciplines can be effectively
synthesized so that QSP can continue to grow as a field.
www.nigms.nih.gov/News/reports/Documents/SystemsPharmaWPSorger2011.pdf
Are you interested in receiving updates and participating in SIG discussions? Join the ISoP QSP SIG today, click here. You can also participate in the QSP discussion forum at http://discuss.go-isop.org/c/systems-pharmacology
For additional information regarding the QSP SIG, please visit our google site: https://sites.google.com/view/isopqspsig/home